Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Won-Seog Kim(Samsung Medical Center), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology), Sabarish Ayyappan(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Srikanth Ambati(Regeneron (United States)), Tran‐Der Tan(Koo Foundation Sun Yat-Sen Cancer Center), Hesham Mohamed(Bristol-Myers Squibb (United States)), H. Miles Prince(Peter MacCallum Cancer Centre), Cecilia Carpio(Universitat Autònoma de Barcelona), Melanie Ufkin(Regeneron (United States)), Isidro Jarque(Hospital Universitari i Politècnic La Fe), Seok‐Goo Cho(The Catholic University of Korea Seoul St. Mary's Hospital), Sung Yong Oh(Korea University Medical Center), Elżbieta Iskierka‐Jazdzewska(Copernicus Memorial Hospital), Min Zhu(Eye & ENT Hospital of Fudan University), Tae Min Kim(Seoul National University Hospital), Jingjin Li(Inner Mongolia Agricultural University), Michelle Poon(National University Hospital), Antonio Gutiérrez(Hospital Universitario Son Dureta), Aafia Chaudhry(Regeneron (United States)), Francesca Lim(Singapore General Hospital)
Cited by 28
Related Papers
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657